News

TB R&D Weekly Update: Podcast Interview with Dr. Tawanda Gumbo

Dr. Tawanda Gumbo

Listen to Tawanda Gumbo Podcast

Summary: Dr. Tawanda Gumbo, an associate professor at the The University of Texas Southwestern Medical Center, recently published a paper in the Journal of Infectious Diseases entitled “Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.” The paper puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB but instead that the differences or fluctuations in the way patients absorb, metabolize and retain the drug in their bodies contributes to the emergence of resistance to TB drugs. In this interview, we discuss the recently published paper, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs.

Dr. Gumbo’s research is focused on advanced pharmacometrics, antimicrobial pharmacokinetic-pharmacodynamics and pharmacogenetics, clinical trial simulations using Monte Carlo Methods, individualized Bayesian dose optimization, as well as, the molecular and cellular pharmacology of antituberculosis and other antimycobacterial agents.

Additional TB R&D News:

Recent exchange on the topic of Moxifloxacin use:

Rational use of moxifloxacin for tuberculosis treatment

Moxifloxacin for tuberculosis (Mendel & Springsklee)

Moxifloxacin for tuberculosis (Singh, et al.)

Moxifloxacin for tuberculosis — Authors’ reply

Other news links:

SymptomsofTuberculosis.Net Launches to Address Rising Concerns Over Tuberculosis and Symptoms of Tuberculosis

Biomedical company sets up in Memphis

Combating TB, the right way

Polio eradication has a lesson for TB control

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...